Peninsula company stock soars as it plots approval of rare liver disease drug
Mirum Pharmaceuticals will start filing paperwork in third-quarter 2020 for FDA approval of its drug in children with Alagille syndrome.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Children | Health Management | Liver | Liver Disease | Urology & Nephrology